Johnson & Johnson (JNJ) Asset Utilization Ratio (2009 - 2026)
Johnson & Johnson recorded quarterly Asset Utilization Ratio of 0.48 in Q1 2026, little changed quarter-over-quarter from 0.48 in Q4 2025, and up 0.77% year-over-year from 0.48 in Q1 2025.
Johnson & Johnson's Asset Utilization Ratio history runs 18 years deep, the most recent figure standing at 0.48 for Q1 2026.
- In Q1 2026, Asset Utilization Ratio rose 0.77% year-over-year to 0.48; the TTM figure through Mar 2026 stood at 0.48 (up 0.77% YoY), while the FY2025 annual figure was 0.5, down 2.8% from the prior year.
- Asset Utilization Ratio came in at 0.48 for Q1 2026 at Johnson & Johnson, roughly flat from 0.48 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.51 in Q4 2023 to a low of 0.42 in Q2 2023.
- A 5-year average of 0.48 and a median of 0.48 in 2025 frame the typical range for Asset Utilization Ratio.
- Across the five-year window, Asset Utilization Ratio slipped 14.21% in 2023 and advanced 19.32% in 2024, its largest moves.
- Johnson & Johnson's Asset Utilization Ratio stood at 0.47 in 2022, then gained by 8.01% to 0.51 in 2023, then declined by 2.91% to 0.5 in 2024, then retreated by 3.05% to 0.48 in 2025, then increased by 0.24% to 0.48 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.48, 0.48, and 0.48 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 0.63 |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 0.48 |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 0.46 |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 0.50 |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 0.41 |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 0.52 |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 0.12 |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 0.55 |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 0.48 |
| Dec 28, 2025 | 0.48 |
| Sep 28, 2025 | 0.48 |
| Jun 29, 2025 | 0.47 |
| Mar 30, 2025 | 0.48 |
| Dec 29, 2024 | 0.50 |
| Sep 29, 2024 | 0.49 |
| Jun 30, 2024 | 0.49 |
| Mar 31, 2024 | 0.50 |
| Dec 31, 2023 | 0.51 |
| Oct 1, 2023 | 0.47 |
| Jul 2, 2023 | 0.42 |
| Apr 2, 2023 | 0.42 |
| Jan 1, 2023 | 0.44 |
| Oct 2, 2022 | 0.47 |
| Jul 3, 2022 | 0.49 |
| Apr 3, 2022 | 0.49 |
| Oct 3, 2021 | 0.51 |
| Jul 4, 2021 | 0.51 |
| Apr 4, 2021 | 0.48 |
| Jan 3, 2021 | 0.48 |
| Sep 27, 2020 | 0.49 |
| Jun 28, 2020 | 0.51 |
| Mar 29, 2020 | 0.53 |
| Dec 29, 2019 | 0.52 |
| Sep 29, 2019 | 0.53 |
| Jun 30, 2019 | 0.53 |
| Mar 31, 2019 | 0.54 |
| Dec 30, 2018 | 0.53 |
| Sep 30, 2018 | 0.52 |
| Jul 1, 2018 | 0.52 |
| Apr 1, 2018 | 0.50 |
| Dec 31, 2017 | 0.49 |
| Oct 1, 2017 | 0.48 |
| Jul 2, 2017 | 0.49 |
| Apr 2, 2017 | 0.50 |
| Jan 1, 2017 | 0.51 |
| Oct 2, 2016 | 0.51 |
| Jul 3, 2016 | 0.51 |
| Apr 3, 2016 | 0.52 |
| Jan 3, 2016 | 0.53 |
| Sep 27, 2015 | 0.53 |
| Jun 28, 2015 | 0.55 |
| Mar 29, 2015 | 0.57 |
| Dec 28, 2014 | 0.57 |
| Sep 28, 2014 | 0.56 |
| Jun 29, 2014 | 0.55 |
| Mar 30, 2014 | 0.54 |
| Dec 29, 2013 | 0.55 |
| Sep 29, 2013 | 0.56 |
| Jun 30, 2013 | 0.57 |
| Mar 31, 2013 | 0.56 |
| Dec 30, 2012 | 0.56 |
| Sep 30, 2012 | 0.56 |
| Jul 1, 2012 | 0.56 |
| Apr 1, 2012 | 0.57 |
| Jan 1, 2012 | 0.58 |
| Oct 2, 2011 | 0.58 |
| Jul 3, 2011 | 0.58 |
| Apr 3, 2011 | 0.59 |
| Jan 2, 2011 | 0.61 |
| Oct 3, 2010 | 0.66 |
| Jul 4, 2010 | 0.67 |
| Apr 4, 2010 | 0.66 |
| Jan 3, 2010 | 0.66 |
| Sep 27, 2009 | 0.68 |